Scisparc Ltd (SPRC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scisparc Ltd (SPRC) has a cash flow conversion efficiency ratio of -0.442x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.28 Million) by net assets ($5.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Scisparc Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Scisparc Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Scisparc Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scisparc Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scisparc Ltd ranked by their cash flow conversion efficiency. Explore how high is Scisparc Ltd's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biotrend Cevre ve Enerji Yatirimlari AS
IS:BIOEN
|
0.021x |
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
0.023x |
|
ELEMENT 29 RESOURCES INC
F:2IK
|
-0.018x |
|
WMG Holdings Bhd
KLSE:6378
|
-0.090x |
|
Cheer Time Enterprise Co Ltd
TW:3229
|
-0.031x |
|
Sage Group PLC
LSE:SGE
|
0.393x |
|
Winchester Bancorp, Inc. Common Stock
NASDAQ:WSBK
|
0.011x |
|
Century Land Joint Stock Company
VN:CRE
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Scisparc Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scisparc Ltd from 2006 to 2025. View SPRC stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.15 Million | $-4.14 Million | -0.804x | -40.77% |
| 2024-12-31 | $8.94 Million | $-5.10 Million | -0.571x | +7.02% |
| 2023-12-31 | $9.59 Million | $-5.89 Million | -0.614x | +49.98% |
| 2022-12-31 | $6.45 Million | $-7.92 Million | -1.228x | -97.47% |
| 2021-12-31 | $8.14 Million | $-5.06 Million | -0.622x | +79.36% |
| 2020-12-31 | $1.43 Million | $-4.31 Million | -3.012x | +99.10% |
| 2019-12-31 | $14.00K | $-4.70 Million | -335.429x | -262.14% |
| 2018-12-31 | $77.00K | $-7.13 Million | -92.623x | -16869.15% |
| 2017-12-31 | $8.39 Million | $-4.58 Million | -0.546x | +78.87% |
| 2016-12-31 | $572.71K | $-1.48 Million | -2.583x | -125.51% |
| 2015-12-31 | $1.15 Million | $-1.32 Million | -1.145x | -107.05% |
| 2014-12-31 | $-116.33K | $-1.89 Million | 16.243x | +689.94% |
| 2013-12-31 | $995.26K | $-2.74 Million | -2.753x | +72.88% |
| 2012-12-31 | $389.43K | $-3.95 Million | -10.152x | -690.49% |
| 2011-12-31 | $2.95 Million | $-3.78 Million | -1.284x | -73.45% |
| 2010-12-31 | $5.09 Million | $-3.77 Million | -0.740x | -118.68% |
| 2009-12-31 | $5.64 Million | $-1.91 Million | -0.339x | +21.07% |
| 2008-12-31 | $7.52 Million | $-3.22 Million | -0.429x | -27.13% |
| 2007-12-31 | $9.41 Million | $-3.18 Million | -0.337x | -61.31% |
| 2006-12-31 | $6.98 Million | $-1.46 Million | -0.209x | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more